Global Glioblastoma Multiforme Therapeutics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

  • receipt Report ID : 144753
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 131
  • list Pharmaceuticals and Healthcare

Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or the neuron. The one which develops in the glial cells (astrocytes and oligodendrocytes) is called glioma, the commonest forms of brain tumor. 

Scope of the Report:

This report focuses on the Glioblastoma Multiforme Therapeutics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Currently unavailable therapies and prognosis for the treatment of GBM is expected to impact the market growth positively through to 2022. Presence of the treatment options which do not increase the overall survival rate in patients such as surgical resection, which is followed by chemotherapy and radiotherapy, is another factor attributing towards the expected growth of this market. Moreover, the fact that glioma stem cells resist conventional treatments also raises urgent need for alternative treatment therapies for glioblastoma multiforme thus driving the market. Increasing R&D in gene therapy and molecular biotechnology for the treatment of CNS associated disorders and cancer is anticipated to fuel the market growth over the forecast period. However, high expenditure involved in research employing genomics based research is a key restraint for market.

The worldwide market for Glioblastoma Multiforme Therapeutics is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

Arbor Pharmaceuticals

Bristol-Myers Squibb

Eisai

F. Hoffmann-La Roche

Merck

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Temozolomide

Bevacozumab

Carmustine

Market Segment by Applications, can be divided into

Hospitals

Clinics

Others

There are 15 Chapters to deeply display the global Glioblastoma Multiforme Therapeutics market.

Chapter 1, to describe Glioblastoma Multiforme Therapeutics Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Glioblastoma Multiforme Therapeutics, with sales, revenue, and price of Glioblastoma Multiforme Therapeutics, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Glioblastoma Multiforme Therapeutics, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Glioblastoma Multiforme Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Glioblastoma Multiforme Therapeutics sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

1.1 Glioblastoma Multiforme Therapeutics Introduction

1.2 Market Analysis by Type

1.2.1 Temozolomide

1.2.2 Bevacozumab

1.2.3 Carmustine

1.3 Market Analysis by Applications

1.3.1 Hospitals

1.3.2 Clinics

1.3.3 Others

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Arbor Pharmaceuticals

2.1.1 Business Overview

2.1.2 Glioblastoma Multiforme Therapeutics Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Arbor Pharmaceuticals Glioblastoma Multiforme Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 Bristol-Myers Squibb

2.2.1 Business Overview

2.2.2 Glioblastoma Multiforme Therapeutics Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Bristol-Myers Squibb Glioblastoma Multiforme Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 Eisai

2.3.1 Business Overview

2.3.2 Glioblastoma Multiforme Therapeutics Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Eisai Glioblastoma Multiforme Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 F. Hoffmann-La Roche

2.4.1 Business Overview

2.4.2 Glioblastoma Multiforme Therapeutics Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 F. Hoffmann-La Roche Glioblastoma Multiforme Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5 Merck

2.5.1 Business Overview

2.5.2 Glioblastoma Multiforme Therapeutics Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Merck Glioblastoma Multiforme Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Glioblastoma Multiforme Therapeutics Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global Glioblastoma Multiforme Therapeutics Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Glioblastoma Multiforme Therapeutics Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 Glioblastoma Multiforme Therapeutics Manufacturer Market Share in 2017

3.3.2 Top 6 Glioblastoma Multiforme Therapeutics Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global Glioblastoma Multiforme Therapeutics Market Analysis by Regions

4.1 Global Glioblastoma Multiforme Therapeutics Sales, Revenue and Market Share by Regions

4.1.1 Global Glioblastoma Multiforme Therapeutics Sales and Market Share by Regions (2013-2018)

4.1.2 Global Glioblastoma Multiforme Therapeutics Revenue and Market Share by Regions (2013-2018)

4.2 North America Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

4.3 Europe Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

4.5 South America Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

5 North America Glioblastoma Multiforme Therapeutics by Countries

5.1 North America Glioblastoma Multiforme Therapeutics Sales, Revenue and Market Share by Countries

5.1.1 North America Glioblastoma Multiforme Therapeutics Sales and Market Share by Countries (2013-2018)

5.1.2 North America Glioblastoma Multiforme Therapeutics Revenue and Market Share by Countries (2013-2018)

5.2 United States Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

5.3 Canada Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

5.4 Mexico Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

6 Europe Glioblastoma Multiforme Therapeutics by Countries

6.1 Europe Glioblastoma Multiforme Therapeutics Sales, Revenue and Market Share by Countries

6.1.1 Europe Glioblastoma Multiforme Therapeutics Sales and Market Share by Countries (2013-2018)

6.1.2 Europe Glioblastoma Multiforme Therapeutics Revenue and Market Share by Countries (2013-2018)

6.2 Germany Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

6.3 UK Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

6.4 France Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

6.5 Russia Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

6.6 Italy Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

7 Asia-Pacific Glioblastoma Multiforme Therapeutics by Countries

7.1 Asia-Pacific Glioblastoma Multiforme Therapeutics Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Glioblastoma Multiforme Therapeutics Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific Glioblastoma Multiforme Therapeutics Revenue and Market Share by Countries (2013-2018)

7.2 China Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

7.3 Japan Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

7.4 Korea Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

7.5 India Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

7.6 Southeast Asia Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

8 South America Glioblastoma Multiforme Therapeutics by Countries

8.1 South America Glioblastoma Multiforme Therapeutics Sales, Revenue and Market Share by Countries

8.1.1 South America Glioblastoma Multiforme Therapeutics Sales and Market Share by Countries (2013-2018)

8.1.2 South America Glioblastoma Multiforme Therapeutics Revenue and Market Share by Countries (2013-2018)

8.2 Brazil Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

8.3 Argentina Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

8.4 Colombia Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

9 Middle East and Africa Glioblastoma Multiforme Therapeutics by Countries

9.1 Middle East and Africa Glioblastoma Multiforme Therapeutics Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Glioblastoma Multiforme Therapeutics Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa Glioblastoma Multiforme Therapeutics Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

9.3 UAE Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

9.4 Egypt Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

9.5 Nigeria Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

9.6 South Africa Glioblastoma Multiforme Therapeutics Sales and Growth Rate (2013-2018)

10 Global Glioblastoma Multiforme Therapeutics Market Segment by Type

10.1 Global Glioblastoma Multiforme Therapeutics Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Glioblastoma Multiforme Therapeutics Sales and Market Share by Type (2013-2018)

10.1.2 Global Glioblastoma Multiforme Therapeutics Revenue and Market Share by Type (2013-2018)

10.2 Temozolomide Sales Growth and Price

10.2.1 Global Temozolomide Sales Growth (2013-2018)

10.2.2 Global Temozolomide Price (2013-2018)

10.3 Bevacozumab Sales Growth and Price

10.3.1 Global Bevacozumab Sales Growth (2013-2018)

10.3.2 Global Bevacozumab Price (2013-2018)

10.4 Carmustine Sales Growth and Price

10.4.1 Global Carmustine Sales Growth (2013-2018)

10.4.2 Global Carmustine Price (2013-2018)

11 Global Glioblastoma Multiforme Therapeutics Market Segment by Application

11.1 Global Glioblastoma Multiforme Therapeutics Sales Market Share by Application (2013-2018)

11.2 Hospitals Sales Growth (2013-2018)

11.3 Clinics Sales Growth (2013-2018)

11.4 Others Sales Growth (2013-2018)

12 Glioblastoma Multiforme Therapeutics Market Forecast (2018-2023)

12.1 Global Glioblastoma Multiforme Therapeutics Sales, Revenue and Growth Rate (2018-2023)

12.2 Glioblastoma Multiforme Therapeutics Market Forecast by Regions (2018-2023)

12.2.1 North America Glioblastoma Multiforme Therapeutics Market Forecast (2018-2023)

12.2.2 Europe Glioblastoma Multiforme Therapeutics Market Forecast (2018-2023)

12.2.3 Asia-Pacific Glioblastoma Multiforme Therapeutics Market Forecast (2018-2023)

12.2.4 South America Glioblastoma Multiforme Therapeutics Market Forecast (2018-2023)

12.2.5 Middle East and Africa Glioblastoma Multiforme Therapeutics Market Forecast (2018-2023)

12.3 Glioblastoma Multiforme Therapeutics Market Forecast by Type (2018-2023)

12.3.1 Global Glioblastoma Multiforme Therapeutics Sales Forecast by Type (2018-2023)

12.3.2 Global Glioblastoma Multiforme Therapeutics Market Share Forecast by Type (2018-2023)

12.4 Glioblastoma Multiforme Therapeutics Market Forecast by Application (2018-2023)

12.4.1 Global Glioblastoma Multiforme Therapeutics Sales Forecast by Application (2018-2023)

12.4.2 Global Glioblastoma Multiforme Therapeutics Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

List of Tables and Figures

Figure Glioblastoma Multiforme Therapeutics Picture

Table Product Specifications of Glioblastoma Multiforme Therapeutics

Figure Global Sales Market Share of Glioblastoma Mu

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery